Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
NCT00069966
Unknown
RATIONALE: Drugs used in chemotherapy, such as pixantrone, cytarabine, methylprednisolone, and cisplatin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed aggressive non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2009
Locations: Baylor University Medical Center, Dallas, Texas +1 locations
Conditions: Lymphoma
Register for Updates
IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
NCT00229723
Completed
The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (X-rays) plus chemotherapy (cisplatin) in terms of local disease control (progression-free) rate at 2 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2009
Locations: Research Site, Dallas, Texas
Conditions: Neoplasms, Squamous Cell
Register for Updates
Study of Talabostat and Cisplatin in Advanced Melanoma
NCT00083252
Completed
The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2007
Locations: Mary Crowley Medical Research Center, Dallas, Texas +1 locations
Conditions: Melanoma, Skin Cancer
Register for Updates
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer
NCT00101842
Completed
The purposes of this study are: To determine the maximum tolerated dose of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine in patients with advanced or metastatic transitional cell carcinoma of the urothelium; To determine the safety of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine and any side effects that might be associated with the combination of these drugs; To determine whether Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine can help patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/24/2006
Locations: For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Dallas, Texas
Conditions: Carcinoma, Transitional Cell
Register for Updates